Streetbeat News

ORTX

Orchard Therapeutics plc

Employees

207

Industry

Research and Development in Biotechnology

orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Stifel analyst Dae Gon Ha has downgraded Orchard Therapeutics (NASDAQ:ORTX) from Buy to Hold and set a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 2:36 pm

Despite a general downturn in the U.S. stock market, several stocks recorded gains. Orchard Therapeutics surged 97.7% after agreeing to be acquired by Kyowa Kirin. SP Plus Corporation jumped 47.5% following the announcement of its acquisition by Metropolis Technologies. Euronav NV climbed 17.3% amid discussions with Frontline and CMB NV. Lamb Weston Holdings gained 12.2% after reporting better-than-expected Q1 results. VEON Ltd. rose 9.6% after its Beeline Uzbekistan opened the Beeline Academy. Other stocks that gained include Immunovant, TransAlta Corporation, Dada Nexus Limited, Live Oak Bancshares, United Natural Foods, and Ur-Energy Inc.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 2:09 pm

U.S. stocks traded lower following the release of economic reports. The Dow, NASDAQ, and S&P 500 all fell. U.S. initial jobless claims rose by 2,000 to 207,000. Orchard Therapeutics, Meiwu Technology, and SP Plus Corporation saw significant stock increases, while Cambium Networks, Gaucho Group Holdings, and Nanobiotix experienced drops. The U.S. trade gap shrank to $58.3 billion in August, the lowest since Sept. 2020.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 1:44 pm

Orchard Therapeutics shares rose by 95.5% in pre-market trading after the company announced a deal to be acquired by Kyowa Kirin Co., Ltd. for a total value of about $477.6 million. Other pre-market gainers include Meiwu Technology, Molekule Group, Femasys, NKGen Biotech, Grom Social Enterprises, Better Choice Company, Momentus, China SXT Pharmaceuticals, and Tenaya Therapeutics. Pre-market losers include Cambium Networks, SIGNA Sports United, MaxCyte, Neoleukin Therapeutics, Safety Shot, Benson Hill, Inspirato, Accolade, and SeaStar Medical Holding Corporation.

Portfolio Pulse from Lisa Levin

October 05, 2023 | 12:15 pm

Orchard Therapeutics Plc (NASDAQ:ORTX) has agreed to be acquired by Japan-based pharmaceutical company Kyowa Kirin Co. for $16.00 per American Depositary Share (ADS), a 144% premium over the previous 30-day average. An additional $1.00 contingent value right (CVR) will be paid for $17.00 per ADS if conditions are met. The acquisition will allow Kyowa Kirin to maximize the value of Orchard's Libmeldy and accelerate the development of Orchard's other programs. The deal is expected to close in Q1 2024.

Portfolio Pulse from Nabaparna Bhattacharya

October 05, 2023 | 10:25 am

Orchard Therapeutics has agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash, with an additional contingent value right of $1.00 per ADS. This has led to a rise in Orchard Therapeutics' share price.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 10:19 am

Kyowa Kirin, a Japan-based pharmaceutical company, has announced a definitive agreement to acquire Orchard Therapeutics for $16.00 per American Depositary Share (ADS) in cash, totaling approximately $387.4 million. Additionally, Orchard shareholders will hold a contingent value right (CVR) of $1.00 per ADS, potentially increasing the total value of the deal to $477.6 million if certain conditions are met.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 7:46 am

Orchard Therapeutics (NASDAQ:ORTX) announced that the FDA has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review. The agency has set a goal date of March 18, 2024.

Portfolio Pulse from Charles Gross

September 18, 2023 | 11:37 am

Orchard Therapeutics has announced that the FDA has accepted its Biologics License Application for OTL-200, a gene therapy for Metachromatic Leukodystrophy (MLD), and granted it priority review status. This could potentially expedite the approval process for the therapy.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2023 | 11:01 am

Oppenheimer analyst Kevin DeGeeter has reiterated his 'Outperform' rating on Orchard Therapeutics (NASDAQ:ORTX), maintaining a price target of $34.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.